Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Core Laboratories (CLB) EPS (Weighted Average and Diluted) (2022 - 2026)

Core Laboratories filings provide 5 years of EPS (Weighted Average and Diluted) readings, the most recent being -$0.02 for Q1 2026.

  • On a quarterly basis, EPS (Weighted Average and Diluted) changed N/A to -$0.02 in Q1 2026 year-over-year; TTM through Mar 2026 was $0.64, a 10.34% increase, with the full-year FY2025 number at $0.65, down 1.52% from a year prior.
  • EPS (Weighted Average and Diluted) hit -$0.02 in Q1 2026 for Core Laboratories, down from $0.13 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.48 in Q2 2023 to a low of -$0.02 in Q1 2026.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was $0.15 (2022), compared with a mean of $0.17.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): plummeted 73.33% in 2023 and later skyrocketed 250.0% in 2024.
  • Core Laboratories' EPS (Weighted Average and Diluted) stood at $0.15 in 2022, then plummeted by 73.33% to $0.04 in 2023, then skyrocketed by 250.0% to $0.14 in 2024, then dropped by 7.14% to $0.13 in 2025, then plummeted by 115.38% to -$0.02 in 2026.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$0.02 (Q1 2026), $0.13 (Q4 2025), and $0.3 (Q3 2025) per Business Quant data.